WuXi PharmaTech (Cayman) Inc. and Eli Lilly and Co. have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China. The once-daily oral agent, discovered by Lilly, has the potential to address cardiovascular risk in patients with dyslipidemia. An estimated 276 million patients in China are affected by these conditions. The drug aims to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides at high risk of ca...